Trials / Conditions / Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8

Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8

11 registered clinical trials studyying Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8 — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advance NCT04391049	NRG Oncology	Phase 1
Active Not Recruiting	Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Eso NCT04460937	National Cancer Institute (NCI)	Phase 1
Recruiting	NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer NCT04615013	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma NCT04111172	Thomas Jefferson University	Phase 2
Completed	Real-Time Monitoring of Chemotherapy Side-Effects in Patients With Gastrointestinal Cancers, RT-CAMSS Study NCT04449679	Thomas Jefferson University	N/A
Completed	Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes NCT04501913	City of Hope Medical Center	—
Completed	Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esopha NCT04097028	Roswell Park Cancer Institute	Phase 2
Completed	Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes NCT04183218	Mayo Clinic	—
Withdrawn	Nutritional Supplementation in Reducing Complications in Patients With Locally Advanced Esophageal Cancer Unde NCT04029857	M.D. Anderson Cancer Center	Phase 3
Active Not Recruiting	Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal NCT03784326	M.D. Anderson Cancer Center	Phase 2
Completed	Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma NCT03395847	M.D. Anderson Cancer Center	EARLY_Phase 1